

RNAi for Therapeutic Market 2016 World Technology,Development,Trends and Opportunities Market Research Report to 2021

PUNE, INDIA, November 9, 2016
/EINPresswire.com/ --

WiseGuyReports.Com Publish a New Market Research Report On –“RNAi for Therapeutic Market 2016 World Technology,Development,Trends and Opportunities Market Research Report to 2021”.

[RNA interference \(RNAi\) is a biological process](#) in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Scope of the Report:

This report focuses on the RNAi for Therapeutic in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/731692-global-rnai-for-therapeutic-forecast-to-2021>

For more information or any query mail at sales@wiseguyreports.com



Market Segment by Manufacturers, this report covers

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

Market Segment by Type, covers

siRNA

miRNA

shRNA

Market Segment by Applications, can be divided into

Cancer

Cardiovascular

HBV

Other

Complete Report Details @ <https://www.wiseguyreports.com/reports/731692-global-rnai-for-therapeutic-forecast-to-2021>

Table Of Contents – Major Key Points

Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021

1 Market Overview

1.1 RNAi for Therapeutic Introduction

1.2 Market Analysis by Type

1.2.1 siRNA

1.2.2 miRNA

1.2.3 shRNA

1.3 Market Analysis by Applications

1.3.1 Cancer

1.3.2 Cardiovascular

1.3.3 HBV

1.4 Market Analysis by Regions

1.4.1 North America (USA, Canada and Mexico)

1.4.1.1 USA

1.4.1.2 Canada

1.4.1.3 Mexico

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany

1.4.2.2 France

1.4.2.3 UK

1.4.2.4 Russia

1.4.2.5 Italy

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China

1.4.3.2 Japan

1.4.3.3 Korea

1.4.3.4 India

1.4.3.5 Southeast Asia

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil

1.4.4.2 Egypt

1.4.4.3 Saudi Arabia

1.4.4.4 South Africa

1.4.4.5 Nigeria

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Alnylam Pharmaceuticals

2.1.1 Business Overview

2.1.2 RNAi for Therapeutic Type and Applications

2.1.2.1 Type 1

2.1.2.2 Type 2

2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and

Market Share

2.2 Arbutus Biopharma (Tekmira)

2.2.1 Business Overview

2.2.2 RNAi for Therapeutic Type and Applications

2.2.2.1 Type 1

2.2.2.2 Type 2

2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.3 Arrowhead

2.3.1 Business Overview

2.3.2 RNAi for Therapeutic Type and Applications

2.3.2.1 Type 1

2.3.2.2 Type 2

2.3.3 Arrowhead RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.4 Dicerna Pharmaceuticals

2.4.1 Business Overview

2.4.2 RNAi for Therapeutic Type and Applications

2.4.2.1 Type 1

2.4.2.2 Type 2

2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.5 Mirna Therapeutics

2.5.1 Business Overview

2.5.2 RNAi for Therapeutic Type and Applications

2.5.2.1 Type 1

2.5.2.2 Type 2

2.5.3 Mirna Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.6 Quark Pharmaceuticals

2.6.1 Business Overview

2.6.2 RNAi for Therapeutic Type and Applications

2.6.2.1 Type 1

2.6.2.2 Type 2

2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.7 RXi Pharmaceuticals

2.7.1 Business Overview

2.7.2 RNAi for Therapeutic Type and Applications

2.7.2.1 Type 1

2.7.2.2 Type 2

2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.8 Silence Therapeutics

2.8.1 Business Overview

2.8.2 RNAi for Therapeutic Type and Applications

2.8.2.1 Type 1

2.8.2.2 Type 2

2.8.3 Silence Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.9 Benitec Biopharma

2.9.1 Business Overview

2.9.2 RNAi for Therapeutic Type and Applications

2.9.2.1 Type 1

2.9.2.2 Type 2

2.9.3 Benitec Biopharma RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.10 miRagen Therapeutics

2.10.1 Business Overview

2.10.2 RNAi for Therapeutic Type and Applications

2.10.2.1 Type 1

2.10.2.2 Type 2

2.10.3 miRagen Therapeutics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.11 Sylentis

2.11.1 Business Overview

2.11.2 RNAi for Therapeutic Type and Applications

2.11.2.1 Type 1

2.11.2.2 Type 2

2.11.3 Sylentis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.12 Gradalis

2.12.1 Business Overview

2.12.2 RNAi for Therapeutic Type and Applications

2.12.2.1 Type 1

2.12.2.2 Type 2

2.12.3 Gradalis RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.13 Sirnaomics

2.13.1 Business Overview

2.13.2 RNAi for Therapeutic Type and Applications

2.13.2.1 Type 1

2.13.2.2 Type 2

2.13.3 Sirnaomics RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

2.14 Silenseed

2.14.1 Business Overview

2.14.2 RNAi for Therapeutic Type and Applications

2.14.2.1 Type 1

2.14.2.2 Type 2

2.14.3 Silenseed RNAi for Therapeutic Sales, Price, Revenue, Gross Margin and Market Share

3 Global RNAi for Therapeutic Market Competition, by Manufacturer

3.1 Global RNAi for Therapeutic Sales and Market Share by Manufacturer

3.2 Global RNAi for Therapeutic Revenue and Market Share by Manufacturer

3.3 Market Concentration Rate

3.3.1 Top 3 RNAi for Therapeutic Manufacturer Market Share

3.3.2 Top 6 RNAi for Therapeutic Manufacturer Market Share

3.4 Market Competition Trend

4 Global RNAi for Therapeutic Market Analysis by Regions

4.1 Global RNAi for Therapeutic Sales, Revenue and Market Share by Regions

4.1.1 Global RNAi for Therapeutic Sales by Regions (2011-2016)

4.1.2 Global RNAi for Therapeutic Revenue by Regions (2011-2016)

.....CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=731692

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353152566>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.